Seung Kwon Koh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seung Kwon Koh has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Duck Cho
Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Hantae Jo
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications - Jeehun Park
Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University, Chuncheon, Korea
2 shared publications - Jinho Kim
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications Bohwa Han
Department of Materials Science and Engineering, Seoul National University, Seoul, Republic of Korea
1 shared publication- Chan Hyuk Kim
Research Institute of Pharmaceutical Sciences, Seoul National University, Gwanak-gu, Seoul, Korea (the Republic of)
1 shared publication
Latest Publications
- Open Access
- 24 July 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 180-189
Optimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products
Hantae Jo, Ph.D., Yujung Jo, B.S., Seung Kwon Koh, B.S., Mijeong Lee, Ph.D., Jinho Kim, Ph.D., SoonHo Kweon, Ph.D., Jeehun Park, Ph.D., Hyun‑Young Kim, M.D., Ph.D., and Duck Cho, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0168
- 24 July 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 180-189
Open AccessOptimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products
Hantae Jo, Ph.D., Yujung Jo, B.S., Seung Kwon Koh, B.S., Mijeong Lee, Ph.D., Jinho Kim, Ph.D., SoonHo Kweon, Ph.D., Jeehun Park, Ph.D., Hyun‑Young Kim, M.D., Ph.D., and Duck Cho, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0168
- Open Access
- 27 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (9) , 956-969
Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.
- 27 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (9) , 956-969
Open AccessAnti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.
- Open Access
- 1 November 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (6) , 638-649
Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used
Seung Kwon Koh , B.S., Jeehun Park , Ph.D., Seong-Eun Kim , B.S., Yuree Lim , M.S., Minh-Trang Thi Phan , Ph.D., Jinho Kim , B.S., Ilwoong Hwang , M.D., Yong-Oon Ahn , Ph.D., Sue Shin , M.D., Junsang Doh , Ph.D., and Duck Cho , M.D.. Ann Lab Med 2022;42:638-49. https://doi.org/10.3343/alm.2022.42.6.638
- 1 November 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (6) , 638-649
Open AccessNatural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used
Seung Kwon Koh , B.S., Jeehun Park , Ph.D., Seong-Eun Kim , B.S., Yuree Lim , M.S., Minh-Trang Thi Phan , Ph.D., Jinho Kim , B.S., Ilwoong Hwang , M.D., Yong-Oon Ahn , Ph.D., Sue Shin , M.D., Junsang Doh , Ph.D., and Duck Cho , M.D.. Ann Lab Med 2022;42:638-49. https://doi.org/10.3343/alm.2022.42.6.638
- Open Access
- 12 February 2021
- Published by Wiley in Advanced Biology
- Vol. 5 (2) , 2170021
Lymphatic Vessel Networks: Modeling 3D Human Tumor Lymphatic Vessel Network Using High‐Throughput Platform (Adv. Biology 2/2021)
- 12 February 2021
- Published by Wiley in Advanced Biology
- Vol. 5 (2) , 2170021
Open AccessLymphatic Vessel Networks: Modeling 3D Human Tumor Lymphatic Vessel Network Using High‐Throughput Platform (Adv. Biology 2/2021)
- Open Access
- 1 January 1992
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 7 (2) , 136-140
Spinal bone mineral density of normal and osteoporotic women in Korea
Koh SK, et al. J Korean Med Sci. 1992 Jun;7(2):136-140. http://dx.doi.org/10.3346/jkms.1992.7.2.136
- 1 January 1992
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 7 (2) , 136-140
Open AccessSpinal bone mineral density of normal and osteoporotic women in Korea
Koh SK, et al. J Korean Med Sci. 1992 Jun;7(2):136-140. http://dx.doi.org/10.3346/jkms.1992.7.2.136